共 50 条
- [1] First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumorsJOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9Li, TianhongLoRusso, PatriciaMaitland, Michael L.Ou, Sai-Hong IgnatiusBahceci, ErkutBall, Howard A.Park, Jung WookYuen, GeoffreyTolcher, Anthony
- [2] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Harvey, R. DonaldFalchook, Gerald StevenNaqash, Abdul RafehKim, Joseph W.Dowlati, AfshinLe Bruchec, YvanCoudert, IsabelleErvin-Haynes, Annette L.Sommerhalder, David
- [3] Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Patnaik, AmitaLoRusso, PatriciaBall, Howard A.Bahceci, ErkutYuen, GeoffreyPapadopoulos, Kyriakos P.Kittaneh, MuaiadTolcher, Anthony W.
- [4] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224Infante, Jeffrey R.Mendelson, David S.Burris, Howard A., IIIBendell, Johanna C.Tolcher, Anthony W.Gordon, Michael S.Gillenwater, Heidi H.Arastu-Kapur, ShirinWong, Hansen L.Papadopoulos, Kyriakos P.
- [5] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumorsInvestigational New Drugs, 2016, 34 : 216 - 224Jeffrey R. InfanteDavid S. MendelsonHoward A. BurrisJohanna C. BendellAnthony W. TolcherMichael S. GordonHeidi H. GillenwaterShirin Arastu-KapurHansen L. WongKyriakos P. Papadopoulos
- [6] A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumorsFRONTIERS IN IMMUNOLOGY, 2023, 14Huang, ZhiyuXu, YanjunHong, WeiGong, LeiChen, KaiyanQin, JingXie, FajunWang, FengTian, XinMeng, XiangruiFeng, WenleiLi, LingyanZhang, BaihuiKang, XiaoyanFan, Yun
- [7] A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2014, 20 (07) : 1900 - 1909Rodon, JordiTawbi, Hussein A.Thomas, Anne L.Stoller, Ronald G.Turtschi, Christian P.Baselga, JoseSarantopoulos, JohnMahalingam, DevalingamShou, YapingMoles, Melissa A.Yang, LinGranvil, CamilleHurh, EunjuRose, Kristine L.Amakye, Dereck D.Dummer, ReinhardMita, Alain C.
- [8] A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumorsANNALS OF ONCOLOGY, 2023, 34 : S1496 - S1497Yu, X.Zhang, J.Liu, R.Deng, Y.Cai, Y.Sun, Y.Dang, Q.Hong, W.Song, Z.Guo, S.Gao, S.Su, W.Shi, M.Fan, S.Zhang, B.Pan, B.Ren, Y.Wang, J.Zhong, C.Ma, L.
- [9] First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumorsSIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)Li, WeiWang, YongshengXiong, AnwenGao, GeSong, ZhengboZhang, YipingHuang, DingzhiYe, FengWang, QimingLi, ZhihuiLiu, JiayeXu, ChunweiSun, YinghuiLiu, XijieZhou, FeiZhou, Caicun
- [10] Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion studyLANCET ONCOLOGY, 2021, 22 (12): : 1740 - 1751Lakhani, Nehal J.Chow, Laura Q. M.Gainor, Justin F.LoRusso, PatriciaLee, Keun-WookChung, Hyun CheolLee, JeeyunBang, Yung-JueHodi, Frank StephenKim, Won SeogSantana-Davila, RafaelFanning, PhilipSquifflet, PierreJin, FengKuo, Tracy C.Wan, Hong, IPons, JaumeRandolph, Sophia S.Messersmith, Wells A.